{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:05Z","timestamp":1761515885621,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.4158\/ep11302.cr","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T21:11:24Z","timestamp":1326143484000},"page":"e49-e51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insulin Glargine or Neutral Protamine Hagedorn in Patients with Severe Insulin Resistance: is There A Benefit?"],"prefix":"10.1016","volume":"18","author":[{"given":"Vasile M.","family":"Bota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP11302.CR_bb0010","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11302.CR_bb0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2337\/diacare.26.3.590","article-title":"Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart","volume":"26","author":"Vague","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11302.CR_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4158\/EP.15.1.71","article-title":"High-dose insulin therapy: is it time for U-500 insulin?","volume":"15","author":"Lane","year":"2009","journal-title":"Endocr Pract"},{"key":"10.4158\/EP11302.CR_bb0025","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2337\/dc09-2011","article-title":"Dose-response effects of insulin glargine in type 2 diabetes","volume":"33","author":"Wang","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11302.CR_bb0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMra040832","article-title":"Insulin analogues","volume":"352","author":"Hirsch","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP11302.CR_bb0035","unstructured":"Drugstore.com retail price. Available at: http:\/\/www.drugstore.com\/lantus\/10ml-vial-100unitml-solution\/qxn00088222033 http:\/\/www.drugstore.com\/humulin-n\/10ml-vial-100unitml-suspension\/qxn00002831501"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20414715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20414715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/T530234G40M15821.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:54:18Z","timestamp":1761515658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20414715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1530891X20414715"],"URL":"https:\/\/doi.org\/10.4158\/ep11302.cr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin Glargine or Neutral Protamine Hagedorn in Patients with Severe Insulin Resistance: is There A Benefit?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP11302.CR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}